Differential effects of inhibitors of the PI3K/mTOR pathway on the expansion and functionality of regulatory T cells  by Huijts, Charlotte M. et al.
Clinical Immunology 168 (2016) 47–54
Contents lists available at ScienceDirect
Clinical Immunology
j ourna l homepage: www.e lsev ie r .com/ locate /yc l imDifferential effects of inhibitors of the PI3K/mTOR pathway on the
expansion and functionality of regulatory T cellsCharlotte M. Huijts ⁎, Saskia J. Santegoets, Maria Quiles del Rey, Richard R. de Haas, Henk M. Verheul,
Tanja D. de Gruijl, Hans J. van der Vliet ⁎
Department of Medical Oncology, VU University Medical Center, Amsterdam, The NetherlandsAbbreviations: iTregs, in vitro-induced Tregs; LAP, Lat
programmed death-1; pNET, pancreatic neuroendocrine
tensin homolog deleted on chromosome 10; pTregs, per
conventional T cells; Tregs, CD4+CD25hiFOXP3+ regulator
Tregs.
⁎ Corresponding authors at: VU University medical c
Oncology, De Boelelaan 1117, 1081 HV, Amsterdam, The N
E-mail addresses: c.huijts@vumc.nl (C.M. Huijts), jj.van
Vliet).
http://dx.doi.org/10.1016/j.clim.2016.05.005
1521-6616/© 2016 The Authors. Published by Elsevier Inca b s t r a c ta r t i c l e i n f oArticle history:
Received 5 January 2016
Received in revised form 11 April 2016
accepted with revision 13 May 2016
Available online 14 May 2016The PI3K/mTOR pathway is commonly deregulated in cancer. mTOR inhibitors are registered for the treatment of
several solid tumors and novel inhibitors are explored clinically. Notably, this pathway also plays an important
role in immunoregulation. While mTOR inhibitors block cell cycle progression of conventional T cells (Tconv),
they also result in the expansion of CD4+CD25hiFOXP3+ regulatory T cells (Tregs), and this likely limits their
clinical antitumor efﬁcacy. Here, we compared the effects of dual mTOR/PI3K inhibition (using BEZ235) to single
PI3K (using BKM120) or mTOR inhibition (using rapamycin and everolimus) on Treg expansion and functional-
ity. Whereas rapamycin, everolimus and BEZ235 effected a relative expansion beneﬁt for Tregs and increased
their overall suppressive activity, BKM120 allowed for similar expansion rates of Tregs and Tconv without alter-
ing their overall suppressive activity. Therefore, PI3K inhibition alonemight offer antitumor efﬁcacy without the
detrimental selective expansion of Tregs associated with mTOR inhibition.
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mTOR1. Introduction
CD4+CD25hiFoxP3+ regulatory T cells (Tregs) represent a function-
ally distinct lineage of immunoregulatory T cells that have been shown
to be important regulators of immunological tolerance [1]. Tregs are
critically dependent on the transcription factor FoxP3 [2], and play a di-
verse but crucial role in autoimmunity, transplantation and cancer [3].
They can be categorized in three subsets, thymus derived Tregs (tTregs)
whichwere previously named natural Tregs, peripherally derived Tregs
(pTregs) and in vitro-induced Tregs (iTregs) together previously named
induced Tregs [4]. Besides CD3, CD4, CD25 and FoxP3, the absence of the
surface marker CD127 and the presence of several other markers like
CTLA-4 and Helios can be used to deﬁne Tregs [5].
Previous reports have shown that for the in vitro culture of Tregs it is
preferable to add rapamycin, since this would lead to a preferential ex-
pansion of Tregs over conventional T cells (Tconv) [6–8], possibly due to
selective apoptosis of conventional T cells [9]. In addition, Treg enriched
cell populations cultured in the presence of rapamycin retained stableency Associated Peptide; PD-1,
tumor; PTEN, phosphatase and
ipherally derived Tregs; Tconv,
y T cells; tTregs, thymusderived
enter, Department of Medical
etherlands.
dervliet@vumc.nl (H.J. van der
. This is an open access article underFoxP3 expression after in vivo transfer in a murine model [10]. More-
over, in vivo treatmentwith rapamycinwas shown to lead to the expan-
sion of Tregs [11].
Since the mTOR pathway is commonly deregulated in cancer and
mTOR inhibitors have shown efﬁcacy in the treatment of metastatic
renal cell cancer [12], pancreatic neuroendocrine tumor (pNET) [13]
and advanced hormone receptor-positive HER2-negative breast cancer
[14], mTOR inhibitors are now widely used in the treatment of cancer.
However, this could result in the detrimental expansion of Tregs there-
by potentially limiting their clinical antitumor effect.
At this moment, novel inhibitors of the PI3K/mTOR pathway (like
BEZ235 and BKM120) are being explored clinically [15], though their
immunological effects have not been extensively studied. Therefore
we set out to study the effects of dual PI3K/mTOR inhibition compared
to single inhibition of PI3K or mTOR on the expansion and functionality
of Treg enriched cell populations. Our data indicate that whereas single
mTOR inhibition and dual PI3K/mTOR inhibition both effected a relative
expansion beneﬁt for CD25hiFoxP3+ Tregs and increased overall immu-
nosuppressive activity, the PI3K inhibitor BKM120 allowed for similar
expansion rates of Tregs and Tconv and did not alter the overall immu-
nosuppressive activity. In keeping with this observation, BKM120 also
induced lower, although not signiﬁcant, levels of the tTreg-related
markers CTLA-4 andHelios than themTOR single or PI3K/mTORdual in-
hibitors. Therefore, inhibition of PI3K might offer antitumor efﬁcacy
without the detrimental selective Treg expansion that is associated
with the downstream inhibition of mTOR. Apart from potentially in-
creasing the antitumor efﬁcacy of inhibitors of the PI3K/mTORthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tion therapy of inhibitors of this pathway with immunotherapeutic
approaches.
2. Materials and methods
2.1. Cell puriﬁcation
Peripheral Blood Mononuclear Cells (PBMC) were isolated from
buffy coats or heparinized blood of healthy donors by density-gradient
centrifugation with Lymphoprep (Axis-Shield, Olso, Norway). CD4+ T
cells were isolated using the untouched CD4+ T cell isolation kit
(Miltenyi Biotec, Bergisch Gladbach, Germany), according to the
manufacturer's protocol with a mean (±SEM) purity of 93.9% (±2.3).
Next, CD4+CD25+ cells were isolated over two consecutive magnetic
columns using CD25 MicroBeads (Miltenyi Biotec) according to the
manufacturer's protocol with a mean (±SEM) purity of 87% (±2.1)
CD4+CD25+ cells and 63.8% (±2.9) CD25+FoxP3+ cells.
2.2. Cell cultures
MACS puriﬁed CD4+CD25+ T cells were cultured according to a
modiﬁed version of a previously described protocol by Battaglia et al.
[16] CD4+CD25+ T cells were plated at 0.1 × 106/ml in RPMI 1640
(Lonza, Basel, Switzerland) supplemented with 100 I.E./ml sodium
penicillin (Astellas Pharma, Leiden, the Netherlands), 100 μg/ml strep-
tomycin sulphate (Radiumfarma-Fisiofarma, Napels, Italy), 2.0 nM L-
glutamine (Life Technologies, Bleiswijk, the Netherlands), 10% pooled
human AB serum (MP Biomedicals, Ohio, USA) and 0.02 mM pyruvic
acid (Sigma, St. Louis, USA), hereafter referred to as culture medium,
with anti-CD3/anti-CD28 Ab-coated magnetic Dynabeads (CD3/CD28
beads, Dynal Biotech/Invitrogen Life Technologies) with a bead to cell
ratio of 1:2 in the presence or absence of rapamycin (Calbiochem,
Merck Millipore, Darmstadt, Germany), the mTOR inhibitor RAD001
(everolimus), the dual PI3K/mTOR inhibitor BEZ235 or the single pan
PI3K inhibitor BKM120 (received from Novartis, Basel, Switzerland) at
the indicated concentrations. At day 2 post activation IL-2 (500 IU/mL,
Proleukin, Novartis, Arnhem, The Netherlands) was added. Cultures
were split and provided with fresh medium containing IL-2 with or
without drugs on day 6 and day 9. On day 10 cells were harvested,
washed and rested in culture medium containing 5% pooled human
AB serum and low dose IL-2 (50 IU/mL). After three days cells were har-
vested and used for functional and phenotypic analysis. In the cultures,
Tregs were deﬁned as CD3+CD4+CD25hiFoxP3+ cells and Tconv were
deﬁned as all other CD3+CD4+ cells present in the cultures.
2.3. Flow cytometry
Cells were analyzed by ﬂow cytometry using FITC labeled antibodies
against CD4 and CD25 (both BD Biosciences, New Jersey, USA), PE la-
beled antibodies against CD147 (eBioscience, San Diego, USA),
CD45RA (BD Biosciences) CD121b and Tim-3 (both R&D systems, Min-
neapolis, USA), PerCP-Cy5.5 labeled antibodies against CD3 and CD4
(BD Biosciences) and APC labeled antibodies against CD25 (BD Biosci-
ences), CCR7, LAP (both R&D systems), and PD-1 (BD Biosciences).
Stainings were performed in PBS supplemented with 0.1% BSA and
0.02% sodium-azide for 30 min at 4 °C.
Intracellular stainings were performed after ﬁxation and perme-
abilization using a ﬁxation/permeabilization kit according to
manufacturer's protocol (eBioscience). FoxP3 was stained with either
PCH101 PE (eBioscience) or 259D Alexa Fluor 488 (Biolegend, San
Diego, USA) anti-FoxP3 mAbs. Intracellular stainings for Helios, CTLA-4
and Ki-67 were performed using FITC labeled Helios (Biolegend) and
PE-labeled CTLA-4 (BD Biosciences) and Ki-67 (BD Biosciences). Before
intracellular IL-2 staining, cells were stimulated for 4 h with 50 ng/mL
PMA and 500 ng/mL ionomycin in the presence of brefeldin A (1:500;Golgiplug, BD Biosciences) and subsequently stained for CD25, CD4,
FoxP3 and IL-2 (BD Biosciences), using the eBioscience ﬁxation/perme-
abilization kit. Live cells were gated based on forward and side scatter
and analyzed on a BD FACSCalibur (BD Biosciences) using CellQuest or
Kaluza Analysis Software (Beckman Coulter).2.4. Western blot
The expression of PI3K/mTOR pathway proteins was determined
in freshly isolated CD4+CD25+ T cells, cultured in the presence of
rapamycin, RAD001, BEZ235 or BKM120, IL-2100 IU/mL and anti-CD3/
anti-CD28 Ab-coated magnetic Dynabeads. After 24 h cells were har-
vested, washed with PBS and lysed with Sample Diluent Concentrate 2
(R&D systems) supplemented with Halt Protease and Phosphatase In-
hibitor Cocktail (Thermo Scientiﬁc, Life Technologies). After sonication
(Soniprep 150, amplitude 18, for 3 times 5 s with 10 s time intervals,
on ice) cells were centrifuged at 10,000g for 10 min at 4 °C. The
supernatant was collected and protein concentration was determined
using the Pierce BCA Protein Assay Kit (Thermo Scientiﬁc, Life Technolo-
gies). Equal amounts (10–20 μg) of protein from each sample were sep-
arated on 10% SDS polyacrylamide gels and subsequently transferred to
PVDFmembranes (Immobilon-FL, Millipore, Carrigtohill, Ireland). Mem-
branes were incubated with primary antibodies phospho-Akt (Ser473,
mouse) total Akt (rabbit), phospho-p70S6K (Thr389, mouse), and total
p-70S6K (rabbit, all from Cell Signaling, Danvers, Massachusetts) as
speciﬁed in themanufacturer's protocol, and speciﬁc bindingwas visual-
ized by using species-speciﬁc HRP conjugated immunoglobulin G,
followed by enhanced chemiluminescent detection and exposure to
ECL X-ray ﬁlm. Anti-β-actin (A5441) (Sigma-Aldrich, St. Louis, USA)
was used as a loading control. Bands were quantiﬁed by analysis of
ﬁlms using the Image J Program, and values were corrected using the
corresponding β-actin protein band and normalized to untreated
samples.2.5. Suppression assay
The capacity of Treg enriched cell populations to suppress prolifera-
tion of allogeneic CD8+ T responder cells was determined by labeling
responder T cells with 1 μM CFSE (Sigma-Aldrich) for a subsequent
culture in a 96 well round-bottom plate at a concentration of
5 × 104 cells/well in culture medium in the presence of 1 μg/mL
anti-CD3 mAb, 1 μg/mL anti-CD28 mAb (clones 16A9 and 15E8,
kindly provided by Dr. René van Lier, Sanquin, Amsterdam, the
Netherlands) and 20 U/mL rhIL-2 with or without the addition of
Treg enriched cell populations in a Treg enriched cell/T responder
ratio of 1:1, 1:2 and 1:4. After 4 days of co-culture, cells were stained
with APC labeled CD8 (BD Biosciences) and proliferation of CD8+
responder T cells was analyzed by assessing CFSE dilution.
Relative proliferation was calculated by the equation % prolifera-
tion = (% responder T cells that proliferated when cultured in the
presence of Treg enriched cells/% responder T cells that proliferated
when cultured alone) × 100 and relative suppression was calculated
by the equation % suppression = 100 – [(% responder T cells that
proliferated when cultured in the presence of Treg enriched cells/%
responder T cells that proliferated when cultured alone) × 100].2.6. Statistical analysis
One-way or two-way repeatedmeasures ANOVAwas used to deter-
mine statistical signiﬁcance of differences between groups with
Bonferroni or Dunn's post-tests. Findings were considered statistical-
ly signiﬁcant when p-values were ≤0.05, as indicated with asterisks
(* p ≤ 0.05, ** p b 0.01, *** p b 0.001). Statistical analyses were per-
formed using GraphPad Prism software (version 5.02, 2008).
49C.M. Huijts et al. / Clinical Immunology 168 (2016) 47–543. Results
3.1. Blocking efﬁcacy of PI3K/mTOR inhibitors
CD4+CD25+ Treg enriched cell populationswith amean CD4 purity
(±SEM) of 93.9% (±2.3), and a mean FoxP3 purity (±SEM) of 63.8%
(±2.9) were cultured in the presence of three PI3K/mTOR pathway in-
hibitors that are either clinically approved or in clinical testing. The
mTOR inhibitor RAD001 (everolimus), the dual PI3K/mTOR inhibitor
BEZ235 and the single pan PI3K inhibitor BKM120 were used in order
to investigate the effect of inhibiting different proteins of the PI3K/
mTOR pathway on the in vitro expansion and functionality of Treg
enriched cell populations. Since these inhibitorswere not previously de-
scribed as used for the culture of Tregs or other T cells, Treg enriched cell
populationswere ﬁrst cultured in a concentration range of each of these
drugs to assess what concentration resulted in maximal purity and
highest intensity of FoxP3 expression. For RAD001, BEZ235 and
BKM120 this optimal concentrationwas 100 nM, 1 μMand 1 μMrespec-
tively (data not shown). The effects of these three inhibitors were then
compared with rapamycin (100 nM), the mTOR inhibitor most com-
monly used for the in vitro culture and expansion of Tregs [6–9], and
to a condition where Treg enriched cell populations were cultured in
the presence of medium alone (control condition). To conﬁrm the
blocking efﬁcacy of the inhibitors at the selected concentrations, west-
ern blots were performed. The blocking efﬁcacy on PI3K was assessed
by the amount of phosphorylation of the downstream protein Akt
while the blocking efﬁcacy of the mTOR protein was measured by
assessing phosphorylation of one of its downstream proteins p70S6K.
As shown in Fig. 1, both the dual PI3K/mTOR inhibitor BEZ235 and the
single pan PI3K inhibitor BKM120 efﬁciently blocked PI3K as shown
by reduced expression of phosphorylated Akt compared to the control
condition (Fig. 1A upper panel and Fig. 1B). All inhibitors effectedFig. 1.Western blots ofmTOR signaling proteins. The blocking efﬁcacy of the four PI3K/mTORpa
in the presence of medium (control), rapamycin 100 nM, RAD001 100 nM, BEZ235 1 μM or B
Immunoblots for phospho-Akt (Ser473), total Akt, phospho-p70S6K (Thr389) and total p70S6
using the Image J Program, and values were corrected using the corresponding β-actin protei
Akt; C, quantiﬁcation of phospho-p70S6K and total p70S6K. Data shown are representative forefﬁcient blocking ofmTOR as shown by reduced expression of the phos-
phorylated form of the downstream protein p70S6K compared to the
control condition (Fig. 1A fourth panel and Fig. 1C). In conclusion, the
inhibitors were shown to effectively block their targets in the tested
concentrations and therefore these concentrationswere used for subse-
quent experiments.3.2. mTOR pathway inhibition results in expansion of CD25hiFoxP3+ Tregs
To investigate the effect of rapamycin, RAD001, BEZ235 andBKM120
on the expansion of Treg enriched cell populations, CD4+CD25+ T cells
were cultured for two weeks in the presence of these inhibitors and
anti-CD3/anti-CD28 Ab-coated magnetic Dynabeads (CD3/CD28 beads,
Dynal Biotech/Invitrogen Life Technologies) and IL-2 as described in
the materials and methods section. After two weeks the percentage of
CD25hiFoxP3+ Tregs was determined for each drug condition. As illus-
trated in Fig. 2A, compared to the control condition in which Treg
enriched cell populations were cultured without the addition of a
speciﬁc inhibitor, the presence of any PI3K/mTOR pathway inhibitor
resulted in a higher purity of CD25hiFoxP3+ T cells, with a mean
(±SEM) percentage of 42.1% (±3.7) in the control condition,
72.3% (±2.4) with rapamycin (p b 0.001), 76.5% (±2.8) with
RAD001 (p b 0.001), 71.3% (±4.2) with BEZ235 (p b 0.001), and
61.1% (±3.6) with BKM120 (p b 0.001) (Fig. 2B). The MFI of Foxp3
(Fig. 2C) followed the same trend as shown for the percentages.
Interestingly, the single pan PI3K inhibitor BKM120 resulted in a
lower purity of CD25hiFoxP3+ cells compared to culture conditions
where either the mTOR protein alone was inhibited (i.e. in rapamycin
and RAD001 conditions), or where the dual PI3K/mTOR inhibitor
BEZ235 was used, indicating a more dominant role for mTOR in the se-
lective expansion of Tregs.thway inhibitors were determined in freshly isolated CD4+CD25+ T cells cultured for 24 h
KM120 1 μM, IL-2100 IU/mL and anti-CD3/anti-CD28 Ab-coated magnetic Dynabeads. A,
K. β-actin was used as a loading control. B–C, Bands were quantiﬁed by analysis of ﬁlms
n band and normalized to untreated samples; B, quantiﬁcation of phospho-Akt and total
2 independent experiments.
Fig. 2.mTOR inhibition results in expansion of Tregs. A, Representative dot plots illustrating the percentages of CD25hiFoxP3+ Tregs determined after twoweeks of culture of Treg enriched
cell populations with IL-2 and anti-CD3/anti-CD28 Ab-coated magnetic Dynabeads in the presence of medium (control), rapamycin, RAD001, BEZ235 or BKM120. B–C, The percentages
(B) of CD25hiFoxP3+ Tregs were assessed by ﬂow cytometry and the mean ﬂuorescence intensity (C) of FoxP3 was determined. Means + SEM are shown; p-values are indicated with
asterisks; * p ≤ 0.05, *** p b 0.001; n= 13; One way repeated measures ANOVA with Bonferroni post-test.
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The in vitro culture of Tregs from peripheral blood is complicated by
the fact that both CD4 and CD25, surface markers commonly used for
isolation of CD4+CD25+ Tregs, can also be expressed by activated
Tconv resulting in a startingpopulation containing both cell types. How-
ever, previous studies have shown that addition of rapamycin to
CD4+CD25+ T cell cultures leads to a selective expansion of Tregs,
due to the apoptosis of Tconv in the presence of rapamycin [9]. To assess
whether the various PI3K/mTOR pathway inhibitors resulted in a pref-
erential expansion of Tregs over Tconv cells, the expansion factors of
absolute numbers of both Tregs, deﬁned as CD25hiFoxP3+ T cells, and
Tconv, deﬁned as all other cells present in the cultures, were calculated
and a ratio was determined. As shown in Fig. 3, while culturing Treg
enriched cell populations in the presence of medium and IL-2 alone
(control condition) resulted in the predominant expansion of Tconv
(mean ratio of 0.5 (±0.07)), both single mTOR inhibition using
rapamycin (mean ratio of 1.6 (±0.2), p b 0.001) or RAD001 (mean
ratio of 2.2 (±0.3), p b 0.001) and dual PI3K/mTOR inhibition using
BEZ235 (mean ratio of 2.3 (±0.6), p b 0.01) supported the preferential
expansion of Tregs. Interestingly, culturing Treg enriched cell popula-
tions in the presence of BKM120 resulted in similar expansion rates of
Tregs and Tconv (mean ratio of 1.1 (±0.2), p = n.s.), indicating that
inhibition of the mTOR pathway upstream of the protein kinase mTOR
diminishes the selective expansion beneﬁt for Tregs.Fig. 3.mTOR inhibition results in a relative expansion beneﬁt for Tregs. Treg enriched cell
populations were cultured for two weeks with IL-2 and anti-CD3/anti-CD28 Ab-coated
magnetic Dynabeads in the presence of medium (control), rapamycin, RAD001, BEZ235
or BKM120. Expansion factors of absolute numbers of both Tregs, deﬁned as
CD25hiFoxP3+ T cells, and Tconv, deﬁned as all other cells present in the cultures, were
calculated and a ratio was determined. Means + SEM are shown; p-values are indicated
with asterisks; ** p b 0.01, *** p b 0.001; n = 13; One way repeated measures ANOVA
with Friedman post-test.3.4. Phenotypic analysis of expanded Tregs
To investigate the phenotypic characteristics of Tregs cultured in the
presence of the different PI3K/mTOR pathway inhibitors, CD25hiFoxP3+
Tregs were analyzed for several Treg-associated markers, as shown in
Fig. 4. The tTreg markers CTLA-4 and Helios were more abundantly
(though not statistically signiﬁcant) expressed by Tregs cultured in
the presence of anmTOR pathway inhibitor compared to Tregs culturedin the control condition,with similar expression levels of KI-67. An anal-
ysis of the expression of two markers associated with activated Tregs,
i.e. CD147 and CD121b [17,18], revealed that bothmarkers were equally
expressed by the CD25hiFoxP3+ Tregs in all ﬁve culture conditions.
Interestingly, while we indeed observed high expression of CD147, the
level of CD121b was substantially lower than was expected based on a
previous report studying activated human regulatory T cells [17,18]. In
addition, the expression of Latency Associated Peptide (LAP), a marker
frequently expressed by activated Tregs and associated with cell
contact-dependent immunosuppression was determined [18–20].
Fig. 4. Phenotypic analysis of expanded Tregs. Treg enriched cell populations were cultured for two weeks with IL-2 and anti-CD3/anti-CD28 Ab-coated magnetic Dynabeads in the
presence of medium (control), rapamycin, RAD001, BEZ235 or BKM120. After two weeks the expression of several Treg associated markers was assessed on CD25hiFoxP3+ Tregs by
ﬂow cytometry. Means + SEM are shown; p-values are indicated with asterisks; * p ≤ 0.05; n= 3–4; One-way repeated measures ANOVA with Bonferroni post-tests.
Fig. 5. IL-2 production of expanded Tregs. A, Representative dot plots of IL-2 production in
CD25hiFoxP3− Tconv and CD25hiFoxP3+ Tregs, cultured in the presence of medium
(control) or rapamycin. B, Bar graph showing the percentage of IL-2 positive cells in Treg
enriched cell populations cultured in medium (control), rapamycin, RAD001, BEZ235 or
BKM120. Means + SEM are shown; p-values are indicated with asterisk; ** p b 0.01,
*** p b 0.001; n= 3; two-way repeated measures ANOVA with Bonferroni post-test.
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of LAP on CD25hiFoxP3+ Tregs cultured in the presence of BKM120.
Compared to the control condition, CD45RA was signiﬁcantly higher
expressed by Tregs cultured in the presence of BEZ235 indicating the
presence of more phenotypically naïve CD25hiFoxP3+ Tregs [21]. No
major differences were observed between the different mTOR pathway
inhibitors with respect to the expression of the inhibitory receptors
Tim-3 and programmed death-1 (PD-1) or the lymphoid migratory
chemokine receptor CCR7.
3.5. Cytokine production by expanded Tregs
Tregs are known to be highly dependent on IL-2 [22] and can, in con-
trast to Tconv, hardly produce this cytokine themselves [23]. To evaluate
the production of IL-2 in our cultures, intracellular stainings for IL-2
were performed. To discriminate between activated Tconv and Tregs,
two populations were gated based on the gating strategy that is
shown in Fig. 2A (i.e. activated Tconv: CD25hiFoxP3− T cells (upper
left quadrants); Treg: CD25hiFoxP3+ T cells (upper right quadrants)).
Representative dot plots of IL-2 production in CD25hiFoxP3− Tconv
and CD25hiFoxP3+ Tregs cultured in the presence of medium (control)
or rapamycin are shown in Fig. 5A. As shown in Fig. 5B, in all ﬁve condi-
tions intracellular IL-2 was primarily produced by Tconv, with only very
low levels being detectable in Tregs. No signiﬁcant differences between
the different mTOR pathway inhibitors were observed with respect to
intracellular IL-2 production.
3.6. mTOR inhibition results in Tregs with suppressive functionality
To evaluate the capacity of the Treg enriched cell populations, cul-
tured in the presence of one of the four different mTOR pathway inhib-
itors, to suppress other T cells, Treg enriched cell populations were
cultured for two weeks with anti-CD3/anti-CD28 Ab-coated magnetic
Dynabeads and IL-2. Subsequently Treg enriched cell populations
were harvested and co-cultured with CFSE labeled CD8+ responder T
cells (Fig. 6A). Cell division of the responder T cells was assessed after
a 4-day co-culture period of responder T cells with different ratios of
Treg enriched cell populations, in the presence of 1 μg/mL anti-CD3
mAb, 1 μg/mL anti-CD28mAb and 20 U/mL IL-2 (Fig. 6B). Cells cultured
in the presence of Dynabeads and IL-2 alone (control condition, Fig. 6A
lower left panel) already reduced the proliferation of responder T cells
Fig. 6.mTOR inhibition results in Tregs with suppressive function and suppression is related to percentage of Tregs in expanded cultures. Treg enriched cell populationswere cultured for
twoweeks with IL-2 and anti-CD3/anti-CD28 Ab-coated magnetic Dynabeads in the presence of medium (control), rapamycin, RAD001, BEZ235 or BKM120. Their capacity to suppress T
cell proliferation was tested by measuring CFSE dilution of stimulated CD8+ responder T cells using anti-CD3 mAb, anti-CD28mAb, and IL-2. A, Representative histograms showing CFSE
dilution of responder T cells in the various conditions. Unstimulated CD8+ responder T cells without the addition of anti-CD3 mAb, anti-CD28 mAb, and IL-2 and CD8+ responder T cells
stimulatedwith anti-CD3mAb, anti-CD28mAb, and IL-2, both without the addition of cultured Treg enriched cell populations (upper two panels) were used as control conditions. Lower
panels show the CFSE dilution of responder T cells cultured with Treg enriched cell populations that were generated in the presence of medium (control), rapamycin, RAD001, BEZ235 or
BKM120. B, Bar graph showing the proliferation of responder T cells cultured with Treg enriched cell populations generated in the presence of medium (control), rapamycin, RAD001,
BEZ235 or BKM120, relative to responder T cells alone in different ratios of cultured Treg enriched cell populations versus responder T cells (1:1, 1:2, 1:4). Means + SEM are shown.
Statistics were performed on the 1:1 ratios of cultured Treg enriched cell populations versus responder T cells. p-values are indicated with asterisks; * p ≤ 0.05, ** p b 0.01; n= 3; One
way repeated measures ANOVA with Bonferroni post-test. C-D, Percentages of CD25hiFoxP3+ Tregs were assessed by ﬂow cytometry. CFSE dilution of CD8+ responder T cells was deter-
mined and represented as suppression of responder T cells relative to CD8+ responder T cells stimulated with anti-CD3 mAb, anti-CD28 mAb, and IL-2. C, The ratio of the percentage of
suppression and the percentage of Tregs. D, Correlation between the frequency of CD25hiFoxP3+ Tregs and the relative suppression of responder T cells. Each point represents an individual
data point, symbols represent the different conditions e.g. open bullet points: no addition of an inhibitor (control○), black bullet points: Treg enriched cell populations generated in the
presence of BKM120 (●), grey bullet points: Treg enriched cell populations generated in the presence of mTOR inhibition, both single mTOR and dual PI3K/mTOR inhibitors ( ).
p-value b 0.01, R = 0.65.
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panel) in which responder T cells were stimulated in the presence of
anti-CD3, anti-CD28 mAb and 20 U/mL IL-2 without the addition of
other cells. This could be explained by the presence of a minor percent-
age of Tregs as noted in Fig. 2, combined with a competition of Tconv inthe control bulk cultures with the responder T cells for growth factors
and nutrients.
Treg enriched cell populations cultured in the presence of an mTOR
inhibitor, either a single mTOR inhibitor (rapamycin or RAD001) or the
dual PI3K/mTOR inhibitor (BEZ235), resulted in a signiﬁcant decrease in
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(p-value compared to control for rapamycin condition p b 0.01,
for RAD001 and BEZ235 p ≤ 0.05). In contrast, Treg enriched cell
populations cultured in the presence of the PI3K inhibitor BKM120
were not able to suppress the proliferation of responder T cells to a sim-
ilar extent as cells cultured in the presence of an mTOR inhibitor, as
shown in Fig. 6B (p-value of control condition compared to BKM120
was not signiﬁcant).
Interestingly, when relating the observed suppression of responder
T cell proliferation to the percentage of Tregs present in the culture,
we found that all four mTOR pathway inhibitors as well as the control
condition showed a similar suppression per Treg (Fig. 6C), indicating
that mTOR inhibition does not appear to enhance the suppressive ca-
pacity per Treg. In addition, a signiﬁcant correlation between the per-
centage of CD25hiFoxP3+ cells within the differentially conditioned
cultures and their suppressive activity (Fig. 6D) was found, indicating
that inhibitors of the PI3K/mTOR pathway modulate immunosuppres-
sion via their effects on the frequency of Tregs.
4. Discussion
Novel PI3K/mTOR pathway inhibitors are currently under clinical in-
vestigation for the treatment of various malignancies [15], however,
suppressive effects on the immune system could be detrimental and
contribute to tumor survival instead of the intended tumor rejection.
Therefore, studying the effect of targeted therapies on the immune sys-
tem could be of additional value.
mTOR inhibitors were originally designed to target the immune sys-
tem for prevention of transplant rejection by inhibiting the activation of
T cells [24]. Although patients treated with these mTOR inhibitors
showed reduced cancer risks [25], it is still quite remarkable that
these inhibitors are now actually used in the treatment of cancer taking
into account the already suppressed state of the immune system in this
disease and the fact that mTOR inhibitors have been shown to induce
in vitro [6–8] as well as in vivo [11] expansion of immunosuppressive
Tregs which are associated with poor prognosis in cancer patients [26,
27]. In addition, we found a more suppressed state of the immune sys-
temwith an increase in circulating Treg frequencies in renal cell cancer
patients treated with everolimus (Huijts CM et al., manuscript in prep-
aration). As lowdosemetronomic cyclophosphamide has been reported
to deplete Tregs in cancer patients [28], we are currently conducting a
phase 1–2 clinical trial in patients with metastatic renal cell cancer in
which standard second line treatment with everolimus is combined
with lowdosemetronomic cyclophosphamide in order to assesswheth-
er preventing the potentially detrimental mTOR inhibitor associated in-
crease in Tregs can result in an enhanced clinical antitumor efﬁcacy of
everolimus [29]. As several PI3K/mTORpathway inhibitors are currently
under development for the treatment of cancer [15], we analyzed three
relatively novel PI3K/mTOR pathway inhibitors for their effects on Tregs
in vitro. Our data show that CD25hiFoxP3+ Tregs have an expansion
beneﬁt over Tconv when cultured in the presence of an mTOR inhibitor
while more upstream inhibition of the mTOR pathway using a PI3K in-
hibitor, leads to similar expansion rates for Tregs and Tconv. Tregs cul-
tured in the presence of either an mTOR inhibitor, a PI3K inhibitor or a
dual PI3K/mTOR inhibitor show an overall similar phenotype character-
ized by the expression of CTLA-4, Helios, KI-67 and CD147 with inter-
mediate/low expression of CD121b, TIM-3, PD-1 and CCR7 and a low
capacity to produce IL-2. The main difference in marker expression
that was observed between the investigated inhibitors was the induc-
tion of LAP expression on Tregs cultured in the presence of BKM120.
As LAP is a marker found on the surface of activated tTregs [18], it is
hard to explain the more abundant expression of this marker on Tregs
cultured in the presence of BKM120, since these Tregs did not show
other characteristics of activated tTregs, such as an increase in suppres-
sion. However, BKM120 also induced lower, although not signiﬁcantly
so, levels of the tTreg-related markers CTLA-4 and Helios than themTOR single or PI3K/mTOR dual inhibitors pointing towards the surviv-
al of tTregs in the presence of an mTOR inhibitor.
When analyzing the suppressive capacities of the Treg enriched cell
populations, we observed that Treg enriched cell populations cultured
in the presence of a singlemTOR or dual PI3K/mTOR inhibitor displayed
an increase in their overall suppressive capacity, while Treg enriched
cell populations cultured in the presence of the PI3K inhibitor did not.
These data indicate that the target site used for inhibiting the PI3K/
mTOR pathway determines the immunosuppressive effect of these
compounds.While inhibition ofmTOR results in the preferential expan-
sion of Tregs over Tconv, it is possible to shift this balance in favor of
Tconv upon more upstream inhibition of the pathway, as shown by
the use of the PI3K inhibitor BKM120.Whether this is due to the inabil-
ity of Tregs to expand or the relative insensitivity of Tconv for PI3K inhi-
bition remains to be elucidated.
Tregs and Tconv differ in their intracellular signaling pathways. Acti-
vation of Tconv results in downregulation of phosphatase and tensin
homolog deleted on chromosome 10 (PTEN), which negatively regu-
lates PI3K, facilitating the activation of the pathway via Akt and mTOR.
However, Tregs are less dependent on the PI3K/mTOR pathway com-
pared to Tconvdue to the constitutive expression of PTEN, even after ac-
tivation [30]. In addition, Tregs were shown to express the protein
kinase PIM2 in a FoxP3 dependent manner [31], allowing them to prog-
ress through cell cycle by the use of the JAK/STAT5 pathwaywithout the
need for themTOR pathway. This could be an explanation for the ability
of Tregs to proliferate in the presence of anmTOR inhibitor while Tconv
cannot. Interestingly however, we observed that culture of Treg
enriched cell populations in the presence of a PI3K inhibitor resulted
in similar expansion rates for Tregs and Tconv, so the proliferation ben-
eﬁt for Tregs seen in the presence of an mTOR inhibitor was lost in the
presence of PI3K inhibition, indicating a more important role for the
PI3K protein in the proliferation of Tregs. This is in line with previously
published results, showing a critical role for PI3K in the function of
Tregs, and in particular the p110δ isoform of PI3K [32]. Additionally,
it was shown that the proliferation and differentiation of Tregs
in vivo is dependent on PI3K activation and that inhibition of PI3K
exerts a stronger effect on Tregs compared to Tconv or cytotoxic
CD8+ T cells [33].
How the proliferation and immunosuppressive function of Tregs is
exactly affected by the inhibitors of the PI3K/mTOR pathway remains
to be elucidated. For example, counterintuitively both upstream inhibi-
tion in the PI3K/mTOR pathway, by inhibiting PI3K [32], as well as over-
expression of themore downstream protein Akt [34], have been shown
to negatively impact Tregs, whereas inhibition of the downstream pro-
tein mTOR results in Treg expansion in vitro and in vivo [6,11], suggest-
ing that there is probably a certain window in the range in the level of
activation of the PI3K/mTOR pathway in which optimal Treg expansion
and function is maintained (also reviewed in Ref. [35]). The apparently
opposing roles of PI3K and mTOR in Tregs were proposed to be ex-
plained by a feedback loop in which mTOR inhibition results in PI3K-
dependent Akt activation [36]. Importantly, in our study dual inhibition
of both PI3K and mTOR by BEZ235 resulted in the preferential prolifer-
ation of Tregs (as was also observed with mTOR inhibition alone), indi-
cating that inhibition of mTOR is dominant over PI3K inhibition in
inducing expansion of Tregs. In line with this observation are data
reporting comparable effects of rapamycin and BEZ235 on Treg differ-
entiation [37]. Together, these data therefore indicate that the proposed
feedback loop cannot completely explain the observed effects. Other
possible explanations include direct interactions between PI3K and
STAT5, as observed in hematologic malignances, whereby inhibition of
PI3K can result in the inhibition of STAT5, thereby inhibitingprogression
through cell cycle [38]. Alternatively, some of the observed results could
be explained by effects of the inhibitors on Tconv instead of Tregs.
Indeed, studies have also indicated that mTOR inhibitors may lead to
selective Treg expansion due to apoptosis of Tconv [9]. Furthermore, re-
cent observations showed Tregs to be more sensitive to PI3K inhibition
54 C.M. Huijts et al. / Clinical Immunology 168 (2016) 47–54compared to Tconv, which could give Tconv the opportunity to prefer-
entially proliferate in the presence of PI3K inhibitors [36].
Interestingly, although mTOR inhibition resulted in an increase in
the immunosuppressive capacity of the total Treg cell enriched popula-
tion, this was caused by an increase in the frequency of Tregs and not by
an increase in the suppressive capacity of individual Tregs, as we found
that the suppression per Treg was similar in all culture conditions.
In conclusion, therapies targeting the PI3K/mTOR pathway can re-
sult in detrimental immunological effects that may limit the develop-
ment of effective antitumor immune responses. Here we demonstrate
that PI3K-targeted inhibition of the PI3K/mTOR pathway using PI3K in-
hibition, is not accompanied by the preferential expansion of Tregs that
we andothers have observedusingmTOR inhibitors, and therebydonot
contribute to a more immune suppressive state. Therefore, PI3K inhibi-
tors could be a suitable, perhaps clinically more effective, alternative
for mTOR inhibition in the treatment of cancer, without detrimental
predominant Treg expansion.
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